Profitability
Weight: 25%
B+
76
- 5yr Avg ROIC 14.1%
- Operating Margin Trend +0.62 pp/yr
HALO
Halozyme Therapeutics, Inc.
AlphaQuality composite grade, weighted for platform & compounding fcf businesses.
Capital Efficiency
Weight: 15%
A+
99
- 5yr Avg ROE 675.0%
- 5yr Share-Count CAGR -4.1%
Growth Quality
Weight: 25%
B
71
- 5yr Revenue CAGR 33.2%
- 5yr EPS CAGR -1.7%
- Revenue-Growth Years (5) 5/5
Cash Generation
Weight: 20%
A+
98
- 5yr FCF Margin 48.0%
- 5yr FCF/NI Conversion 1.26x
Balance Sheet
Weight: 10%
A-
83
- Net Debt / EBITDA 2.21x
- Interest Coverage (EBIT/Int) 45.03x
- Altman Z-Score 4.00
Stability
Weight: 5%
C
57
- EPS Volatility (σ/μ) 0.55
- Piotroski F-Score 6
- Negative-Revenue Years (5) 0/5
Guru Flow
Curated superinvestor sentiment — not part of the AlphaQuality grade.3 of 3 gurus held; 1 added; 2 trimmed.
- Holders
- 3
- Avg Δ position
- -12.6%
- New buys
- 0
- Full exits
- 0
- Cooperman decreased -99%
- Greenblatt increased +70%
- Dalio decreased -9%